<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02452255</url>
  </required_header>
  <id_info>
    <org_study_id>14-0441</org_study_id>
    <secondary_id>NIH RO1GM056687</secondary_id>
    <nct_id>NCT02452255</nct_id>
  </id_info>
  <brief_title>Fenofibrate and Propranolol in Burn Patients</brief_title>
  <official_title>Mechanisms of Fenofibrate and Propranolol Alone or Combined in Burn Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shriners Hospitals for Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study will test the hypothesis that Propranolol, fenofibrate and fenofibrate
      plus propranolol have therapeutic, physiological, and metabolic effects that will improve
      clinical outcomes, and the long-term recovery, rehabilitation, and QOL in burned patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Determine the clinical benefits and underlying mechanisms whereby the metabolic perturbators
      fenofibrate and propranolol impact burn patient outcomes. The investigators hypothesize that
      these metabolic regulators given for one year will maintain body mass, improve muscle
      function by increasing protein synthesis, augment wound healing, reduce fibrosis, improve
      cardiovascular function, reduce systemic inflammation, restore insulin sensitivity, and
      decrease liver dysfunction without the risk of the hypoglycemia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose Metabolism</measure>
    <time_frame>From randomization up to one year</time_frame>
    <description>Glucose levels and amount of regular insulin infused during hospitalization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypermetabolism</measure>
    <time_frame>From randomization up to one year</time_frame>
    <description>Resting energy expenditure (REE) done weekly while in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate pressure product</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an average of 5 weeks</time_frame>
    <description>Multiply the subjects resting heart rate and systolic blood pressure measurements and average every 24 hours while hospitalized</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Burn</condition>
  <arm_group>
    <arm_group_label>Fenofibrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fenofibrate by mouth given daily throughout hospitalization for up to 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fenofibrate and Propranolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fenofibrate and Propranolol by mouth given throughout hospitalization for up to 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo by mouth given daily throughout hospitalization for up to 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propranolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propranolol by mouth given throughout hospitalization for up to 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate</intervention_name>
    <description>Fenofibrate by mouth given daily throughout hospitalization for up to 12 months</description>
    <arm_group_label>Fenofibrate</arm_group_label>
    <arm_group_label>Fenofibrate and Propranolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo by mouth given daily throughout hospitalization for up to 12 months</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>Propranolol by mouth given daily throughout hospitalization for up to 12 months</description>
    <arm_group_label>Fenofibrate and Propranolol</arm_group_label>
    <arm_group_label>Propranolol</arm_group_label>
    <other_name>Metroprolol</other_name>
    <other_name>inderal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  0 through 80 years

          -  â‰¥ 20% TBSA Burn injury

        Exclusion Criteria:

        Pregnancy

        History or existence of pre-burn injury conditions

          -  Allergies to propranolol or fenofibrate

          -  Asthma requiring treatment

          -  Congestive heart failure (measured ejection fraction &lt; 20%)

          -  Renal or hepatic disease

          -  Medical condition requiring glucocorticoid treatment

          -  History of AIDS, ARC or HIV

          -  History of Cancer within 5 years

        Decision not to treat due to burn injury severity or futility as deemed by the clinical
        team
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David N Herndon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine Reed, RN</last_name>
    <phone>409-771-6987</phone>
    <email>ca2reed@utmb.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deb Benjamin, RN</last_name>
    <phone>409-770-6731</phone>
    <email>dbenjami@utmb.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shriners Hospitals for Children</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77551</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Reed, BSN</last_name>
      <phone>409-770-6987</phone>
      <email>ca2reed@utmb.edu</email>
    </contact>
    <contact_backup>
      <last_name>Deb Benjamin, MSN</last_name>
      <phone>409-770-6731</phone>
      <email>dbenjami@utmb.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David N Herndon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2015</study_first_submitted>
  <study_first_submitted_qc>May 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2015</study_first_posted>
  <last_update_submitted>June 2, 2017</last_update_submitted>
  <last_update_submitted_qc>June 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

